What is the primary delivery method for Libende?

Libende is administered as an intravenous liposomal dispersion.

Is Libende suitable for patients with cardiac concerns?

Yes, it is indicated for patients with metastatic breast carcinoma for whom anthracycline monotherapy is indicated, including those with an increased cardiac risk.

What are the specific requirements for Kaposi sarcoma patients?

Patients must have disease progression, CD4 counts below 200 cells/mm³, and have received prior combination chemotherapy or be intolerant to such therapy.

Libende Pegylated Liposomal Doxorubicin

Name: Libende Pegylated Liposomal Doxorubicin
Brand: AMEGA Biotech

Libende Pegylated Liposomal Doxorubicin | AMEGA Biotech | mytradeloop

Resumen

Libende is a pegylated liposomal doxorubicin formulation presented as an intravenous injectable dispersion. It is indicated for the treatment of various malignancies, including metastatic ovarian cancer, AIDS-related Kaposi sarcoma, metastatic breast cancer, and multiple myeloma.

Liposomal dispersion
Intravenous injectable

Contactar al fabricante Ver catálogo

Aspectos destacados del producto

Pegylated liposomal formulation
Intravenous injectable dispersion
Indicated for patients with increased cardiac risk in breast cancer therapy

Detalles del producto

Uso	Single-Use
Concentration	20 mg/10ml

Clasificación

Especialidades
Vía de administración
Estado de prescripción
Usage
Forma farmacéutica
Clasificación ATC

Ventajas competitivas

Clinical Indication

Metastatic ovarian carcinoma (refractory to paclitaxel and platinum-based regimens)
AIDS-related Kaposi sarcoma (with low CD4 counts and extensive disease)
Metastatic breast carcinoma (where anthracycline monotherapy is indicated)
Multiple myeloma (in combination with Bortezomib)

Variantes

Documentos